A Prospective Clinical Study On A Total Hip Resurfacing System

NCT ID: NCT00604734

Last Updated: 2019-02-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 280 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-10-31
• Study Completion Date: 2012-10-31

Brief Summary

This prospective clinical study is to demonstrate the efficacy and safety of ReCap Total Hip Resurfacing System.

Detailed Description

The study is designed as a prospective, multi-center, non-randomized study. It is designed to evaluate the effects of metal-on-metal acetabular articulating bearing surfaces.

The device will be used in conjunction with a cemented metal femoral resurfacing prosthesis.

The objective of this clinical investigation is to evaluate the safety and effectiveness of the metal-on-metal Recap Total Resurfacing System.

Performance will be assessed trough Harris Hip Score, radiographic evaluation at various postoperative visits. Adverse events and revisions will be documented for safety assessments.

Primary endpoints:

• Total Harris hip score
• Device revisions or removals

Secondary endpoints:

• Total Harris hip score
• Radiographic changes as evidenced by:

I. Acetabular component migration, change in angle of inclination or presence of osteolysis II. Femoral component subsidence, femoral neck Fracture or presence of osteolysis

Conditions

Arthritis; Avascular Necrosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ReCap

ReCap Total Hip Resurfacing System

Group Type: OTHER

ReCap Total Hip Resurfacing System

Intervention Type: DEVICE

This is a hip resurfacing system.

Interventions

ReCap Total Hip Resurfacing System

This is a hip resurfacing system.

Intervention Type: DEVICE

Other Intervention Names

Total hip resurfacing; ReCap

Eligibility Criteria

Inclusion Criteria

1. Patients with a preoperative Total Harris Hip Score of < 70

2. Conservative treatment has proven unsuccessful

3. Primary hip surgery

4. Patients requiring hip resurfacing for degenerative joint disease (inflammatory or non- inflammatory) or any of the composite diagnoses of:

1. Osteoarthritis

2. Avascular necrosis

3. Legg Perthes

4. Rheumatoid Arthritis

5. Juvenile Rheumatoid Arthritis

6. Systemic Lupus Erythematosus

7. Developmental Dysplasia, which does not prevent stable acetabular reconstruction

8. Post traumatic arthritis S. Patients at least 18 years of age

6. Patients of all races and gender 7. Patients who are able to follow post-operative care instructions 8. Patients who are willing and able to return for scheduled follow-up evaluations 9. Patient has signed the IRB approved Informed Consent Form

Exclusion Criteria

1. Patients with a preoperative Total Harris Hip Score of > 70

2. Previous prosthetic hip replacement device (including other surface arthroplasty, endoprosthesis,etc) in the operative hip

3. Contralateral hip prosthesis (total hip replacement or surface replacement),including staged or simultaneous procedures

4. Developmental dysplasla, which prevents stable acetabular reconstruction

5. Patients with previous Girdlestone procedures

6. Patients with above knee amputation of the contralateral and/or ipsilateral leg

7. Severe osteoarthritis or marked bone loss,which would preclude proper fixation of the prosthetic device(s)

8. Active or suspected systemic or localized Infection

9. Parkinson's or Alzheimer's Disease

10. Patients with severe instability or deformity of the ligaments and/or surrounding soft tissue,which would preclude stability of the prosthesis

11. Patients less than 18 years of age

12. Patients with condition(s) that may Interfere with the survival of the femoral resurfacing or acetabular replacements or their outcomes,including Paget's Disease, Charcot's Disease, Sickle Cell Anemia or traits Severe osteoporosis compromising bone stock (I.e.Dorr type C bone Lower extremity muscular atrophy Neuromuscular disease

13. Patients with a clinical conditions that may limit follow-up,including: immunocompromised conditions, hepatitis, active tuberculosis, neoplastic disease, chronic renal failure, organ transplant recipients, known terminal disease process

14. Patients with a "fused"hip

15. Patients with metal allergy or hypersensitivity

16. Participation in a study of any investigational product (drug or device) within the past 12 months

17. Prisoners,known drug or alcohol abuser,or mentally incompetent individuals

18. Systemic steroids within 6 months

19. Patients with a known malignancy

20. Patients who are pregnant

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zimmer Biomet

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jo De Schepper, MD

Role: PRINCIPAL_INVESTIGATOR

AZ Nikolaas

Locations

Az Nikolaas Campus Sint Niklaas

Sint-Niklaas, , Belgium

Countries

Belgium

Other Identifiers

EU-8

Identifier Type: -

Identifier Source: org_study_id